Accurate assessment of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) status and Ki-67 proliferative index were the key-point to tailor invasive breast cancer treatment. This evidence concerns the gene ERBB2 and invasive breast carcinoma.